Bristol Myers claims Phase 2 success for GPRC5D-directed CAR-T

Phase 2positiveGPRC5D-directed CAR-TPositive

AI Analysis

Summary

Bristol Myers Squibb reported positive Phase 2 results for its GPRC5D-directed CAR-T therapy in multiple myeloma, addressing treatment options for patients with disease progression after CAR-T therapy.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Met

Importance:6/10

Sentiment:

0.70

CAR-Tmultiple myelomaPhase 2 dataoncology

Related Companies

$BMY

Read the original article

Published by Endpoints News on September 8, 2026 2:08 PM

Read Original